Table 1 Characteristics of all the studies included in the meta-analysis
Author | Year | Country | Number of patients | HCR technique | CABG technique | Number of CAD | Extent of CAD | Stents | Staging strategy | Study design | |
|---|---|---|---|---|---|---|---|---|---|---|---|
HCR | CABG | ||||||||||
Hage | 2019 | Canada | 216 | 147 | Robotic-assisted MIDCAB | OPCAB | Double-vessel CAD | LAD with non-LAD lesions | NA | NA | Cohort |
Patel | 2018 | America | 207 | 207 | MIDCAB | CABG/OPCAB | Double-vessel CAD | LAD with circumflex or RCA | DES | Staged: CABG first | Cohort |
Qiu | 2019 | China | 52 | 128 | NA | OPCAB | Double-vessel CAD | LAD with non-LAD lesions | DES | NA | Cohort |
Wu | 2017 | China | 73 | 383 | NA | OPCAB | MVD | LAD with non-LAD lesions | DES | Staged: CABG first | Cohort |
Di Bacco | 2019 | Italy | 89 | 89 | MIDCAB | NA | NA | NA | NA | Staged: PCI first | Cohort |
Hannan | 2020 | American | 302 | 302 | MIDCAB | NA | MVD | LAD with non-LAD lesions | NA | Staged | Cohort |
Shen | 2013 | China | 141 | 141 | MIDCAB | CABG/OPCAB | MVD | LAD with non-LAD lesions | DES | Single-stage | Cohort |
Modrau | 2020 | Denmark | 103 | 103 | MIDCAB/OPCAB | CABG | MVD | LAD with non-LAD lesions | DES | NA | Cohort |
Basman | 2020 | America | 100 | 100 | robotic-assisted MIDCAB | CABG/OPCAB | TVD | NA | DES | Staged: CABG first | Cohort |
Zhao | 2009 | America | 112 | 154 | NA | CABG/OPCAB | NA | NA | NA | Single-stage | Cohort |
Delhaye | 2010 | France | 18 | 18 | NA | CABG/OPCAB | MVD | LAD with non-LAD lesions | DES | Staged: CABG first | Cohort |
Harskamp | 2015 | Netherlands | 306 | 918 | MIDCAB | NA | MVD | NA | DES | Staged | Cohort |
Kon | 2008 | America | 15 | 30 | NA | OPCAB | MVD | LAD with non-LAD lesions | DES | Single-stage | Cohort |
de Cannière | 2001 | America | 20 | 20 | MIDCAB + PTCA | CABG | Double-vessel CAD | LAD with non-LAD lesions | DES or BMS | Staged: PCI first | Cohort |
Farid | 2018 | America | 100 | 82 | MIDCAB | MIDCAB | MVD | LAD with non-LAD lesions | DES or BMS | Staged: CABG first | Cohort |
GÄ…sior | 2014 | Poland | 98 | 102 | MIDCAB/EACAB | CABG/OPCAB | MVD | LAD with non-LAD lesions | DES | NA | RCT |
Ganyukov | 2020 | Russia | 49 | 49 | MIDCAB | CABG | MVD | LAD with non-LAD lesions | DES | Staged: CABG first | RCT |
Esteves | 2020 | Brazil | 40 | 20 | NA | CABG | TVD | NA | NA | Staged: CABG first | RCT |